Writing the Overall Conclusion and Actions Section in a PBRER

Introduction

The Overall Conclusion and Actions section represents the final scientific and regulatory statement within the Periodic Benefit-Risk Evaluation Report (PBRER). It brings together the conclusions reached throughout the report and explains whether any pharmacovigilance or regulatory actions are considered necessary following review of the cumulative evidence available at the Data Lock Point.

Unlike earlier sections that analyse individual aspects of the benefit-risk profile, this section provides a concise summary of the overall assessment. It should confirm the Marketing Authorisation Holder's position regarding the current benefit-risk balance and identify any resulting actions, commitments or changes arising from the evaluation.

The emphasis should remain on communicating the outcome of the scientific assessment rather than repeating the evidence supporting that assessment.

Regulatory Basis

ICH E2C(R2) requires the PBRER to conclude with an overall integrated assessment of the medicinal product and any proposed or completed actions relevant to its safety profile.

Within the European Union, these expectations are reflected in Good Pharmacovigilance Practices (GVP) Module VII.

The conclusion should therefore summarise the outcome of the cumulative evaluation while remaining fully consistent with the scientific discussions presented throughout the report.

Purpose of This Section

This section should answer four questions clearly.

• What is the current overall benefit-risk conclusion?

• Has that conclusion changed since the previous reporting interval?

• What evidence was principally responsible for the conclusion?

• What actions, if any, are proposed or have already been implemented?

The section should not introduce new scientific arguments.

Instead, it should communicate the outcome of the evidence already evaluated within the report.

Relationship to Earlier Sections

Every statement made within the Overall Conclusion should be traceable to discussions presented earlier in the PBRER.

The conclusion should therefore be regarded as the endpoint of the scientific reasoning developed throughout the report rather than an independent assessment.

If readers encounter important information within this section that has not already been discussed elsewhere, the report should normally be revised to incorporate that information into the appropriate preceding section.

Writing Tip

The Overall Conclusion should summarise the destination reached after the scientific journey presented throughout the PBRER. It should never begin a new journey by introducing previously undiscussed evidence.

Principles of Writing the Overall Conclusion

The Overall Conclusion should be concise, balanced and scientifically robust. It should represent the logical culmination of the cumulative evidence presented throughout the PBRER rather than a repetition of the report.

Every conclusion should be supported by discussions presented earlier within the document.

Readers should clearly understand:

• the Marketing Authorisation Holder's overall scientific conclusion;
• whether the benefit-risk balance has changed;
• whether important uncertainties remain;
• whether additional regulatory or pharmacovigilance actions are required.

The emphasis should remain on communicating the outcome of the evaluation rather than repeating the evaluation itself.

Summarising the Benefit-Risk Evaluation

The Overall Conclusion should briefly summarise the principal findings of the Integrated Benefit-Risk Evaluation.

The discussion should address:

• whether the authorised therapeutic benefits remain supported by current evidence;

• whether any important new identified risks have emerged;

• whether important potential risks have been reclassified or better characterised;

• whether areas of missing information have changed;

• whether additional patient exposure has materially influenced understanding of the medicinal product;

• whether the overall benefit-risk balance remains favourable under the authorised conditions of use.

The conclusion should avoid unnecessary repetition of detailed evidence already discussed elsewhere.

Explaining Changes Since the Previous PBRER

One of the most valuable components of the Overall Conclusion is a concise explanation of how scientific understanding has evolved during the reporting interval.

Examples include:

• no meaningful change in the overall benefit-risk balance;

• improved understanding of recognised risks;

• confirmation of previous benefit-risk conclusions through additional cumulative evidence;

• identification of new risk factors requiring product information updates;

• resolution of previously recognised uncertainty;

• refinement of clinical recommendations.

Even where the overall benefit-risk balance remains unchanged, explaining why that conclusion remains appropriate strengthens the scientific quality of the report.

Completed Actions

Where important actions have already been implemented during the reporting interval, these should be summarised briefly.

Examples include:

• updates to the Company Core Safety Information (CCSI);

• revisions to the Reference Safety Information (RSI);

• updates to product information;

• implementation of additional risk minimisation measures;

• completion of PASS;

• closure of important signals;

• implementation of regulatory commitments.

The emphasis should remain on actions that materially influence interpretation of the current benefit-risk profile.

Planned Actions

Where further activities are considered necessary following completion of the PBRER, these should also be summarised.

Examples include:

• additional pharmacovigilance activities;

• initiation or continuation of PASS;

• further signal evaluation;

• updates to the Risk Management Plan;

• enhanced safety monitoring;

• additional educational materials;

• regulatory submissions relating to product information.

Planned activities should arise logically from the cumulative scientific evaluation presented throughout the report.

Where no additional actions are considered necessary, this should be stated clearly.

Distinguishing Scientific Conclusions from Regulatory Actions

Scientific conclusions and regulatory actions are closely related but should not be regarded as synonymous.

A scientific conclusion explains what the cumulative evidence demonstrates.

A regulatory conclusion explains whether that evidence requires changes to the authorised use of the medicinal product.

Operational actions describe how the Marketing Authorisation Holder intends to implement those conclusions.

For example, identification of a new important identified risk may lead to revision of the Company Core Safety Information, updates to the Reference Safety Information, amendments to product information, revision of the Risk Management Plan and implementation of additional pharmacovigilance activities while the overall benefit-risk balance remains favourable.

Clearly distinguishing these concepts improves the transparency of the Overall Conclusion.

Maintaining Consistency

Before finalising the report, authors should confirm that the Overall Conclusion is fully consistent with:

• the Integrated Benefit-Risk Evaluation;

• the Evaluation of Risks section;

• completed Signal Evaluations;

• changes to the Reference Safety Information;

• product information revisions;

• Risk Management Plan updates;

• pharmacovigilance commitments;

• proposed regulatory actions.

Any inconsistency between these sections may reduce confidence in the overall scientific assessment and should be resolved before submission.

Writing Tip

Imagine that the Overall Conclusion is read first by the QPPV, the PRAC Rapporteur or a pharmacovigilance inspector. They should understand the organisation's scientific position, the reasons for that position and the resulting actions without finding contradictions elsewhere in the PBRER.

Common Mistakes

Although the Overall Conclusion is usually one of the shortest sections within a PBRER, it frequently determines the reader's overall impression of the report. A concise conclusion that accurately reflects the scientific evaluation inspires confidence, whereas an inconsistent or unsupported conclusion raises questions about the integrity of the entire report.

The following deficiencies are commonly encountered during internal quality review, regulatory assessment and pharmacovigilance inspections.

Scientific Mistakes

The most frequent scientific error is presenting a conclusion that is stronger than the evidence supports.

Examples include:

• concluding that the benefit-risk balance is unchanged without explaining why;

• implying certainty where important uncertainties remain;

• failing to acknowledge contradictory evidence;

• overstating the importance of isolated findings;

• drawing conclusions that are inconsistent with earlier sections of the PBRER;

• confusing confirmation of the existing safety profile with evidence that the medicinal product has become safer.

The conclusion should accurately reflect both the strengths and the limitations of the cumulative evidence.

Writing Mistakes

Common writing deficiencies include:

• introducing new scientific evidence for the first time in the conclusion;

• repeating entire paragraphs from the Integrated Benefit-Risk Evaluation;

• using generic statements without product-specific justification;

• failing to distinguish scientific conclusions from planned actions;

• presenting operational activities without explaining why they are required;

• excessive repetition of terminology and phrases throughout the report.

The Overall Conclusion should be concise, specific and evidence-based.

Governance Mistakes

The conclusion should remain fully aligned with the organisation's wider pharmacovigilance system.

Examples of governance deficiencies include:

• inconsistency with the Risk Management Plan;

• inconsistency with the Company Core Safety Information (CCSI);

• inconsistency with the Reference Safety Information (RSI);

• omission of agreed pharmacovigilance commitments;

• failure to incorporate important partner information available before the Data Lock Point;

• inconsistency between global and local conclusions without scientific justification.

A well-governed pharmacovigilance system produces conclusions that remain consistent across all regulatory documents.

Inspection and Regulatory Assessment Considerations

During assessment of a PBRER, regulators frequently review the Overall Conclusion before examining the detailed scientific discussions.

Accordingly, reviewers commonly consider whether:

• the conclusion accurately reflects the cumulative evidence;

• important risks and benefits have both been considered;

• scientific uncertainties have been acknowledged appropriately;

• proposed regulatory actions are justified by the evidence;

• the benefit-risk conclusion remains consistent with earlier sections of the report;

• the report demonstrates clear scientific reasoning rather than unsupported assertions.

During pharmacovigilance inspections, inspectors may additionally review:

• the internal review and approval process;

• documentation supporting the final conclusion;

• evidence of QPPV oversight where applicable;

• traceability from signal evaluation through benefit-risk assessment to the final conclusion;

• implementation of actions described in previous PBRERs;

• consistency across global and affiliate pharmacovigilance documentation.

The objective is not to identify a predetermined conclusion but to determine whether the organisation has applied a robust, transparent and reproducible scientific process.

Inspection Insight

An inspector should be able to trace every major statement in the Overall Conclusion back to evidence presented elsewhere in the PBRER and to supporting documentation within the pharmacovigilance system.

Final Pre-submission Review Checklist

Before submission, experienced aggregate physicians perform a final review of the report as a complete scientific document.

Typical questions include:

• Does the Overall Conclusion logically follow from the Integrated Benefit-Risk Evaluation?

• Are all important scientific conclusions supported by evidence presented earlier in the report?

• Are planned pharmacovigilance activities consistent with the identified risks and uncertainties?

• Are product information changes reflected consistently throughout the report?

• Are partner, affiliate and global conclusions scientifically aligned?

• Have all major inconsistencies been resolved?

• Would an independent reviewer reach broadly the same conclusion after reading the report?

A structured final review frequently identifies inconsistencies that individual section authors may overlook.

Key Takeaways

The Overall Conclusion and Actions section represents the final scientific position of the Marketing Authorisation Holder at the Data Lock Point.

It should summarise—not repeat—the cumulative evidence presented throughout the PBRER and clearly explain whether the overall benefit-risk balance has changed, why that conclusion has been reached and what actions have resulted from that assessment.

A high-quality conclusion is concise, evidence-based, internally consistent and fully traceable to the scientific discussions presented elsewhere within the report.

How a Senior Aggregate Physician Thinks

Experienced aggregate physicians recognise that the Overall Conclusion is more than the final section of the PBRER.

It is the point at which months of pharmacovigilance activities, medical review, statistical analysis, signal management, literature evaluation and benefit-risk assessment are distilled into a clear scientific position.

Before approving the report, they ask themselves:

"If this conclusion were challenged by regulators, inspectors or external experts, could every statement be traced to objective evidence within the report?"

If the answer is yes, the conclusion is usually ready for submission.

Continue Reading

• [[writing-the-integrated-benefit-risk-evaluation-section-in-a-pbrer]]
• [[benefit-risk-evaluation-in-pharmacovigilance]]
• [[signal-evaluation-methodology]]
• [[risk-management-plans]]
• [[reference-safety-information-in-pharmacovigilance]]
• [[scientific-writing-in-pharmacovigilance]]
• [[how-to-write-aggregate-safety-reports]]

References

Primary Regulatory References

1. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report.

2. European Medicines Agency. Good Pharmacovigilance Practices (GVP) Module VII – Periodic Safety Update Report.

3. Commission Implementing Regulation (EU) No 520/2012.

4. Directive 2001/83/EC.

5. Regulation (EC) No 726/2004.

Supporting Guidance

1. EMA Questions and Answers on PSURs.

2. EMA Procedural Guidance for PSUSA.

3. Relevant EMA guidance on post-authorisation benefit-risk evaluation.

Scientific References

1. CIOMS Working Group reports on aggregate safety assessment and benefit-risk evaluation.

2. ENCePP Guide on Methodological Standards in Pharmacoepidemiology.

3. ISPE Good Pharmacoepidemiology Practices.

4. Selected peer-reviewed literature on regulatory decision-making, benefit-risk assessment and pharmacovigilance governance.